Targovax ASA: Two abstracts accepted at the SITC Congress
OSLO, Norway, Oct. 6, 2021 /PRNewswire/ -- Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, today announces that two abstracts has been accepted for poster presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting.
The abstracts will be released on the SITC website 9 November 14:00 CEST (www.sitcancer.org/2021/home). The posters are scheduled for presentation during the SITC congress 12-14 November 2021.
The Society for Immunotherapy of Cancer (SITC) Annual Meeting & Pre-Conference Programs brings together stakeholders across the cancer immunotherapy field to advance the science, discover breakthroughs and educate the world on cancer immunotherapy.
As the largest conference solely focused on cancer immunotherapy, the Annual Meeting & Pre-Conference Programs provides international leaders from academia, regulatory and government agencies, as well as industry representatives with a multidisciplinary educational and interactive environment focused on improving outcomes for all cancer patients.
For further information, please contact:
Renate Birkeli, Investor Relations
This information was brought to you by Cision http://news.cision.com
Company Codes: Bloomberg:TRVX@NO, ISIN:NO0010689326, Oslo:TRVX, RICS:TRVX.OL
© 2021 PR Newswire. All Rights Reserved.